 Morrison & Foerster Articles DLA Piper and Morrison & Foerster have scored lead roles on the HK$4bn (£335m) sale of new shares by China's biggest drug distributor Sinopharm.
The deal marks the second H share placement for Sinopharm since its $1.1bn (£714m) IPO in 2009, with 165.7 million shares being sold to between six and 10 non-retail investors at HK$24.60 (£2.06) each. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
